Cisplatin Induced Kidney Toxicity

Launched by THE HOSPITAL FOR SICK CHILDREN · Jun 18, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict and identify kidney damage caused by a chemotherapy drug called cisplatin, which is commonly used to treat various cancers. While cisplatin is effective, it can lead to a serious condition known as acute kidney injury (AKI), affecting 20-50% of patients. The goal of the study is to find specific markers in urine and blood that can help detect the risk of AKI before it happens and even in its early stages, allowing doctors to take preventive measures and improve treatment outcomes for patients.

To be eligible for this trial, participants must be at least 18 years old and starting cisplatin treatment for head, neck, or lung cancers, or children over 3 months old who will receive cisplatin for any cancer. Participants will be asked to provide samples of their urine and blood before and after receiving cisplatin. This research could lead to more personalized treatment plans and better management of kidney health during cancer therapy. If you or a family member are considering this trial, it could offer a chance to contribute to important findings that may help future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult participants: Initiating treatment with CisP (≥75 mg/m2) for head/neck or lung cancers at one of the Adult participating sites; 18 years of age or older.
• • Paediatric participants: Initiating treatment with CisP for any cancer diagnosis at one of the Pediatric participating sites; greater than 3 months of age.
• • All participants: Consent to participate in the study.
• Exclusion Criteria:
• • Diagnosis of chronic kidney disease (CKD) at baseline (glomerular filtration rate \<60 mL/min/1.73m2, determined by chart review of either formal glomerular filtration rate testing, 24 hour creatinine creatinine clearance of age-appropriate serum creatinine-based estimated glomerular filtration rate equations; past kidney transplant)
• • Previous use of any nephrotoxic drugs included on the provided Excluded Nephrotoxic Medications list in the two weeks prior to initiation of CisP treatment
• • Previous use of CisP
• • Previous radiotherapy (total body irradiation or abdominal radiation only) in the last 1 month prior to study
• • Previous hematopoietic stem cell transplant
• • Any chronic or acute health condition that the investigator feels would render the patient inappropriate for this study, including but not limited to significant uncontrolled cardiorespiratory, hepatic, infectious, or renal disease at the discretion of the investigator